Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

<strong>Background<br></strong> The 4-component capsular group B meningococcal vaccine (4CMenB) was licensed as a 4-dose infant schedule but introduced into the United Kingdom as 3 doses at 2, 4, and 12 months of age. We describe the immunogenicity and reactogenicity of the 2 + 1 s...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Valente Pinto, M, O'Connor, D, Galal, U, Clutterbuck, EA, Robinson, H, Plested, E, Bibi, S, Camara Pellisso, S, Hughes, H, Kerridge, S, Mujadidi, YF, Findlow, H, Borrow, R, Snape, MD, Pollard, AJ
Format:	Journal article
Język:	English
Wydane:	Oxford University Press 2020

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

Podobne zapisy